Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06533254 · ClinicalTrials.gov registry record

Behavioral AI to Predict and Increase Peritoneal Dialysis Uptake

A clinical trial of Chronic Kidney Disease, sponsored by Scaled Insights.

Recruiting
Registry status
3,000
Enrollment target
1
Study location

NCT06533254: Recruiting study of Chronic Kidney Disease, sponsored by Scaled Insights.

NCT06533254 is a study of Chronic Kidney Disease that is actively recruiting participants, run by Scaled Insights. The registered enrollment target is 3,000 participants, roughly in line with the 3,177-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06533254, a study of Chronic Kidney Disease, is actively recruiting participants, sponsored by Scaled Insights.

RECRUITING
Registry status
3,000 participants
Enrollment target
1
Study location

Study Summary

Scaled Insights Behavioral AI will be used to improve clinicians ability to detect and understand: The likelihood of patients with kidney failure opting for peritoneal dialysis and to select the right personalized nudge to get CKD patients to choose peritoneal dialysis Scaled Insights' can utilize the data from this study to develop individualized nudges for healthcare professionals that can be broadly deployed within a digital platform so that clinics across the English speaking world can use it as a means of supporting patients with CKD in selecting peritoneal dialysis treatment. Using Scaled Insights novel Behavioral Artificial Intelligence solution, the proposed project has two aims: 1. to identify personality attributes of patients with Chronic Kidney Disease and correlating their personality attributes with their subsequent choice of dialysis. Once correlated into personality based clusters, the AI Model will then be able will determine which personality cluster each net new patient will fall into and therefore predict their specific likelihood of opting for peritoneal dialysis or hemodialysis 2. once prediction is possible, customized nudges towards the selection of PD will be developed and tested to improve the likelihood that patients will opt for peritoneal dialysis Hypotheses: 1. Scaled Insights Behavioral AI will identify the personality characteristics of patients with Chronic Kidney Disease who are likely to opt for both peritoneal dialysis and hemodialysis (Phase 1) 2. Scaled Insights Behavioral AI will identify the nudges that are most effective in encouraging or supporting patients with Chronic Kidney Disease in choosing peritoneal dialysis over hemodialysis (Phase 2)

Primary Outcome

The Investigators will use AI to predict patients choice of dialysis. This choice will be recorded by their clinical provider as per normal routine care.

Conditions Studied

Interventions

  • OTHER Predicting choice of dialysis
  • BEHAVIORAL Behavioral nudges

Study Locations (1)

Texas

  • Dallas Renal Group - Dallas

Trial Details

FieldValue
Enrollment Target 3,000 participants
Start Date 2024-09-01
Est. Completion 2025-12-31
Scaled Insights

1 total trials

What NCT06533254 shows while recruiting

NCT06533254 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 3,177-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target.

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Predicting choice of dialysis is the first listed.

NCT06533254 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06533254 about?

NCT06533254 is a clinical study titled "Behavioral AI to Predict and Increase Peritoneal Dialysis Uptake". Scaled Insights Behavioral AI will be used to improve clinicians ability to detect and understand: The likelihood of patients with kidney failure opting for peritoneal dialysis and to select the right personalized nudge to get CKD patients to choose peritoneal dialysis Scaled Insights' can utilize ...

What is the current status of trial NCT06533254?

This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2024-09-01. Estimated completion is 2025-12-31.

What conditions does trial NCT06533254 study?

This clinical trial studies the following conditions: Chronic Kidney Disease.

What interventions are being tested in trial NCT06533254?

The interventions under investigation include: Predicting choice of dialysis (OTHER), Behavioral nudges (BEHAVIORAL).

Who is sponsoring clinical trial NCT06533254?

This trial is sponsored by Scaled Insights, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06533254 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06533254's enrollment target sits among peer trials

3,000 9th of 101 higher than 93 of 101 other Chronic Kidney Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004847 · 3,000 participants · Phase 1

    Diagnosis of Pheochromocytoma

  • NCT00478712 · 3,000 participants

    Hirschsprung Disease Genetic Study

  • NCT00579566 · 3,000 participants

    Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

  • NCT00816114 · 3,000 participants

    Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06533254, the US trial registry maintained by the National Library of Medicine. NCT06533254 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.